Blocking IL-1 to prevent respiratory failure in COVID-19

COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild respiratory tract infection in the majority of individuals, but in some, it can progress into severe pneumonia and acute respiratory distress syndrome (ARDS). Inflammation is known to play a crucial role in the pathogen...

Descripción completa

Detalles Bibliográficos
Autores principales: van de Veerdonk, Frank L., Netea, Mihai G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411343/
https://www.ncbi.nlm.nih.gov/pubmed/32682440
http://dx.doi.org/10.1186/s13054-020-03166-0
_version_ 1783568357995315200
author van de Veerdonk, Frank L.
Netea, Mihai G.
author_facet van de Veerdonk, Frank L.
Netea, Mihai G.
author_sort van de Veerdonk, Frank L.
collection PubMed
description COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild respiratory tract infection in the majority of individuals, but in some, it can progress into severe pneumonia and acute respiratory distress syndrome (ARDS). Inflammation is known to play a crucial role in the pathogenesis of severe infections and ARDS and evidence is emerging that the IL-1/IL-6 pathway is highly upregulated in patients with severe disease. These findings open new avenues for host-directed therapies in patients with symptomatic SARS-CoV-2 infection and might in addition to antiviral treatment be enough to curb the currently unacceptably high morbidity and mortality associated with COVID-19.
format Online
Article
Text
id pubmed-7411343
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74113432020-08-07 Blocking IL-1 to prevent respiratory failure in COVID-19 van de Veerdonk, Frank L. Netea, Mihai G. Crit Care Review COVID-19 is an emerging disease that can manifest itself as asymptomatic or mild respiratory tract infection in the majority of individuals, but in some, it can progress into severe pneumonia and acute respiratory distress syndrome (ARDS). Inflammation is known to play a crucial role in the pathogenesis of severe infections and ARDS and evidence is emerging that the IL-1/IL-6 pathway is highly upregulated in patients with severe disease. These findings open new avenues for host-directed therapies in patients with symptomatic SARS-CoV-2 infection and might in addition to antiviral treatment be enough to curb the currently unacceptably high morbidity and mortality associated with COVID-19. BioMed Central 2020-07-18 /pmc/articles/PMC7411343/ /pubmed/32682440 http://dx.doi.org/10.1186/s13054-020-03166-0 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Review
van de Veerdonk, Frank L.
Netea, Mihai G.
Blocking IL-1 to prevent respiratory failure in COVID-19
title Blocking IL-1 to prevent respiratory failure in COVID-19
title_full Blocking IL-1 to prevent respiratory failure in COVID-19
title_fullStr Blocking IL-1 to prevent respiratory failure in COVID-19
title_full_unstemmed Blocking IL-1 to prevent respiratory failure in COVID-19
title_short Blocking IL-1 to prevent respiratory failure in COVID-19
title_sort blocking il-1 to prevent respiratory failure in covid-19
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411343/
https://www.ncbi.nlm.nih.gov/pubmed/32682440
http://dx.doi.org/10.1186/s13054-020-03166-0
work_keys_str_mv AT vandeveerdonkfrankl blockingil1topreventrespiratoryfailureincovid19
AT neteamihaig blockingil1topreventrespiratoryfailureincovid19

Ejemplares similares